6505-01-237-5382 ( NDC00173-0367-32 , SEFFIN )
NSN Information
| NSN | FSC | NIIN | Item Name | INC |
|---|---|---|---|---|
| 6505-01-237-5382 | 6505 | 012375382 | CEPHALOTHIN FOR INJECTION,USP | 6666 |
NSN Features
| MRC | Parameter | Characteristics |
|---|---|---|
| SUPP | SUPPLEMENTARY FEATURES | MEDSEP ITEM FOR DOD,GLAXO INC |
| CSCW | TOTAL PRIMARY CONTAINER QUANTITY | 10 |
| CRLK | PRIMARY CONTAINER CONTENT QUANTITY | 1.000 GRAMS OF ACTIVE INGREDIENT |
| AGXW | PHYSICAL FORM | POWDER |
| AKJA | ACTIVE MEDICAMENT MEDICINAL STRENGTH | 1.000 GRAMS CEPHALOTHIN EQUIVALENT |
| CQCT | PRIMARY CONTAINER TYPE | BOTTLE, INFUSION |
| CSGS | ADMINISTRATION | INTRAVENOUS |
Manufacturing Part Numbers (SKUs)
| Part SKU | Cage | Status | RNVC | RNCC | SADC | DAC | RNAAC |
|---|---|---|---|---|---|---|---|
| NDC00173-0367-32 | 34006 | A | 2 | 3 | 6 | 54 | |
| SEFFIN | 34006 | A | 1 | 5 | 6 | 54 |
Manufacturers
| Part SKU | Cage | Manufacturer | Type | Status |
|---|---|---|---|---|
| NDC00173-0367-32 | 34006 | GLAXO WELLCOME INC | A | A |
| SEFFIN | 34006 | GLAXO WELLCOME INC | A | A |
FLIS Identification
| PMIC | ADPE Code | CRITL Code | DEMIL Code | DEMIL INTG | NIIN Asgt | ESD | HMIC | ENAC | Schedule-B | INC |
|---|---|---|---|---|---|---|---|---|---|---|
| A | X | A | 1 | 07/31/1 | P | 3004909185 | 6666 |
FLIS Management
| MOE | REC Rep Code | Mgmt Ctl | USC | Phrase Code | Phrase Statement |
|---|---|---|---|---|---|
| DN | 9L----- | N | V | DISCONTINUED W/O REPLACEMENT | |
| VA | V | K | U/I CONTAINS 10 EA |
Demilitarization Codes & Management
| DML | PMI | HMIC | ADP | CC | ESDC |
|---|---|---|---|---|---|
| A | A | P | X |
Miscellaneous Management
| MOE (S_A) | SOS | AAC | QUP | UI | SLC | CIIC | RC | MCC | SVC |
|---|---|---|---|---|---|---|---|---|---|
| VA | I | 0 | PG | M | U | V | |||
| DN | S9M | Y | 1 | PG | M | U | 9L----- | N |
Management Control Army
| MATCAT 1 | MATCAT 2 | MATCAT 3 | MATCAT 4 5 | ARC |
|---|
Freight
| NMFC | NMFC SUB | UFC | HMC | LTL | LCL | WCC | TCC | SHC | ADC | ACC | ASH | NMF DESC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|